Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
COIL.L
Strong SellSinkerCoiled Therapeutics plc · Healthcare · United Kingdom · $51M · Avg Vol: $7K/d
4
StockRankGet insider-trade alerts
Q
21
V
25
M
24
P/E (TTM)
—
ROE
-138.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Coiled Therapeutics plc, a clinical-stage oncology company, develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally.
FINANCIAL SUMMARY (GBP)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0.2M | 0 | 0 | — | — |
| EPS (GBp) | -0.47 | -0.41 | -0.24 | -0.84 | — | — |
| Shares | 426.8M | 426.8M | 426.8M | 426.8M | 0.0% | 426.8M |
| Debt | — | 0 | 0.4M | 0 | — | — |
| Equity | 7.2M | 5.5M | 4.9M | 2.4M | -30.5% | — |
| Op CF | -1.6M | -1.7M | -0.8M | -0.6M | — | -0.6M |
| Inv CF | -0.1M | -52.6K | 0 | 0 | — | — |
| Fin CF | 3.1M | -58 | 0.6M | 0.4M | — | — |
Loading 1Y...
PRICE (1Y)-15.0%
SMA 50SMA 200
Close
$0.115
RSI (14)
30.0
52W High
$0.4059
From 52W High
0.3%
SCORE BREAKDOWN
Quality
21
ROIC
-139.1%4.4
ROE
-138.9%6.5
GP/Assets
0.0%9.6
Op. Margin
0.0%38.1
FCF/Assets
—N/A
Piotroski
211.9
Int. Cover
-50.0x5.9
D/E Ratio
0.00x98.1
Current Ratio
0.43x2.0
Value
25
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
—N/A
P/S
—N/A
Div Yield
—N/A
Momentum
24
52W High %
28%6.9
RS 6M
-22%38.5
SMA 50/200
0.87x26.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$51M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of COIL.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| COIL.L | Coiled Therapeutics plc(you) | $51M | 4 | Strong Sell |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $52M | 0 | Strong Sell |
| MREO | Mereo BioPharma Group plc | $50M | 12 | Strong Sell |
| OKYO | OKYO Pharma Limited | $88M | 4 | Strong Sell |
| IMM.L | ImmuPharma plc | $30M | 1 | Strong Sell |
| APTA.L | Aptamer Group PLC | $25M | 3 | Strong Sell |
| SBTX.L | SkinBioTherapeutics plc | $33M | 11 | Strong Sell |
| SAR.L | Sareum Holdings plc | $63M | 19 | Strong Sell |
| SCLP.L | Scancell Holdings plc | $141M | 3 | Strong Sell |
| TLSA | Tiziana Life Sciences Ltd | $129M | 1 | Strong Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 56.0%